Phase II study of bevacizumab and irinotecan as second-line therapy in patients with metastatic colorectal cancer previously treated with fluoropyrimidine, oxaliplatin, and bevacizumab
收藏NIAID Data Ecosystem2026-03-07 收录
官方服务：
资源简介：
Interventions: 1) Bevacizumab 10mg/kg is administered by 10-30min. intravenous infusion, followed by irinotecan 150mg/m2 by 90 min infusion (2)Patients should be received this chemotherapy biweekly until disease progression Primary outcome(s): Progression Free Survival Study Design: Single arm Non-randomized
创建时间：
2011-03-15
